Methods
Fabrication of nanostraw microdevices. Unless otherwise noted, all materials were purchased from Sigma-Aldrich (St. Louis, MO). First, two layers of 110 mg/mL 950 kDa PMMA (MicroChem) in anisole were deposited onto a 3-inch-diameter <111> silicon wafer (Addison Engineering) by spin casting at 1350 rpm and curing at 110 °C for 1 min. Microposit S1818 photoresist (MicroChem) was spun cast over the PMMA at 2500 rpm and cured at 110 °C for 1 min. The photoresist was exposed to 225 mJ/cm 2 Testing nanostraw microdevice retention of drug following detachment of microdevices from the silicon wafer. Microdevices were incubated in a PBS solution of 10 mg/mL FITC-insulin overnight, rinsed with PBS, and scraped from the wafer with a razor.
Microdevices were then loaded into a channel formed by placing a 1.5 × 24 × 0.12 mm adhesive spacer (Grace Bio-labs) between a glass slide and coverslip. The microdevices were incubated at room temperature for approximately 30 min and then imaged with brightfield and fluorescence microscopy.
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Determining if device reservoirs become saturated with FITC-dextran after incubation for 48 h. Nanostraw microdevices were incubated in 1 mg/mL FITC-dextran and analyzed with confocal microscopy as performed for the FITC-dextran influx assay, except the timepoints used were 48 and 72 h.
Determining total nanostraw microdevice drug capacity. Devices were loaded with 10 mg/mL FITC-insulin and monitored for drug release as described previously except the mass of drug released was determined at 48 h, after which time no significant drug release was detected. 
